Академический Документы
Профессиональный Документы
Культура Документы
Opinion Leaders
2014
60%
Similar
Different
8%
Different
32%
In-between
71%
Similar
In-between
8%
21%
2015
57%
Similar
Different
14%
Different
29%
In-between
61%
Similar
2%
36%
In-between
25%
17%
23%
45%
24%
50%
46%
30%
34%
46%
18%
Percent Support
Opinion Leaders
85%
82%
83%
80%
83%
77%
73%
75%
68%
55%
Positive sentiment surrounds biosimilar entry to the U.S. market. Most important to
HCPs and Opinion Leaders is prescribers autonomy in decisions about biosimilars.
A call for further education and support services is also expected.
However, considerable segments express ambivalence,
another signal that only a surface-level awareness of biosimilars exists.
Here are some things people have been saying about biosimilars entering the U.S. market.
For each one, please indicate how much you agree or disagree.
Opinion Leaders
Biosimilars can help reduce costs for
patients and the health care system
without compromising patient safety.
21%
71%
8%
61%
30%
9%
25%
68%
64%
32%
5%
7%
80%
84%
11%
20%
5%
0%
78%
75%
17%
5%
2%
27%
23%
48%
64%
9%
39%
14%
Agree
Agree
Disagree
Disagree
APCO Insight interviewed 287 Health Care Opinion Leaders (n=200) and Health Care Providers
(n=87) between October 9-22, 2015. Interviews were conducted online or over the telephone. Health
Care Opinion Leaders were defined as the top 10 percent most active and engaged segment of the
general public. Health Care Providers included generalists, specialists, nurses and pharmacists.
For more information, please visit rorindicator.com or contact Chrystine Zacherau at
czacherau@apcoworldwide.com